Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Table 4 Overall response rate and PFS in 5 randomized trials comparing gemcitabine to gemcitabine plus platinum analog

Reference	Year	n	Treatment regimen	ORR (%)	p	Median PFS/TTP (mo)	p
Louvet	2005	156	Gemcitabine	17.3	0.04	3.7	0.04
		157	Gemcitabine (FDR) + Oxaliplatin	26.8		5.8
Poplin	2006	279	Gemcitabine (standard)	5	--	na	na
		277	Gemcitabine (FDR)	10	--
		276	Gemcitabine (FDR) + Oxaliplatin	9	--
Heinemann	2006	95	Gemcitabine	8.2	--	3.1	0.053
		95	Gemcitabine + Cisplatin	10.2		5.3
Colucci	2002	54	Gemcitabine	9.2	0.02	2.0	0.048
		53	Gemcitabine + Cisplatin	26.4		5.0
Viret	2004	41	Gemcitabine	5	--	2.5	ns
		42	Gemcitabine + Cisplatin	7		2.2

ORR = overall response rate; PFS = progression-free survival; TTP = time-to-progression; FDR = fixed dose rate; na = data not available; ns = not significant;

ISSN: 1471-2407